

Transferkolleg 2010 - Synthetic Biotechnology

The Swiss biotech industry will rise to the challenge of being competitive in the increasingly global marketplace by creating novel products.

Synthetic biotechnology aims to make the engineering of new functions fast, cost-effective, scalable, predictable and safe. Tools to accomplish this undertaking include, among others, DNA sequencing and synthesis, proteomics, metabolomics, genetic chemistry, cell analytics and imaging. This opens up exciting new avenues for innovation.

The Swiss biotech industry has the expertise to meet this challenge by applying these new methods and processes in the following fields: genetic and metabolic engineering, artificial enzymes and biomaterials, biosynthetic pathways, glycobiology, diagnostics and therapy, engineering of tissues, cells and proteins, drug and product safety, biological sensor systems, bioremediation of environmental pollution and many more.

The Transferkolleg on Synthetic Biotechnology will cover all biotech markets. We are soliciting the submission of high potential projects in such fields and will favor interdisciplinary and early stage projects.

Project team

- Dr. Hans-Rudolf Zeller (president)
- Prof. Oreste Ghisalba (Novartis Pharma AG)
- Prof. Daniel Gygax (biotechnet)
- Dr. Karl Knop (formerly CSEM)
- Prof. Klaus Ragaller (formerly ABB)
- Dr. Wilhelm Stark (Hochschule für Life Sciences, FHNW)